Published in Medical Patent Law Weekly, February 7th, 2007
The company also confirmed that it expects fourth quarter earnings of approximately $0.33 per share and full year earnings of approximately $1.17 per share, prior to the cumulative impact of the settlement costs and tax benefit. Fourth quarter revenues are expected to be approximately $69.7 million, at the current First Call consensus. "Revenues increased in all divisions on both a sequential...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly